Our offerings under Rule 506(c) are for accredited investors only.
FOR OUR CURRENT REGULATION A OFFERING, NO SALE MAY BE MADE TO YOU IN THIS OFFERING IF THE AGGREGATE PURCHASE PRICE YOU PAY IS MORE THAN 10% OF THE GREATER OF YOUR ANNUAL INCOME OR NET WORTH. DIFFERENT RULES APPLY TO ACCREDITED INVESTORS AND NON-NATURAL PERSONS. BEFORE MAKING ANY REPRESENTATION THAT YOUR INVESTMENT DOES NOT EXCEED APPLICABLE THRESHOLDS, WE ENCOURAGE YOU TO REVIEW RULE 251(D)(2)(I)(C) OF REGULATION A. FOR GENERAL INFORMATION ON INVESTING, WE ENCOURAGE YOU TO REFER TO WWW.INVESTOR.GOV.

For our anticipated Regulation A offering, until such time that the Offering Statement is qualified by the SEC, no money or consideration is being solicited, and if sent in response prior to qualification, such money will not be accepted. No offer to buy the securities can be accepted and no part of the purchase price can be received until the offering statement is qualified. Any offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time before notice of its acceptance given after the qualification date. A person's indication of interest involves no obligation or commitment of any kind. Our Offering Circular, which is part of the Offering Statement, may be found at www.cardonecapital.com

The Most Successful Entrepreneur in Medicine – Dr. David C. Karli

In this Show

Who is David Karli and Why Do You Need to Know him:
David Karli is a physician, entrepreneur and biomedical thought leader. He is the CEO and owner of Greyledge Technologies, an emerging biotechnology company focused on developing stem cell and biologic therapies. He has been active in developing stem cell science both scientifically and clinically since 2005, personally involved in treating thousands of patients to date, including numerous elite-level and professional athletes. In addition, he maintains executive and consulting roles within the biotech, sports medicine, fitness, age management and wellness business sectors. He continues to lead the effort required to refine the practice of regenerative medicine, and has published pivotal clinical results and lectured extensively. Dr. Karli has been featured in high-level media publications such as the Wall Street Journal, New York Times, ESPN Magazine and Denver Magazine.
Show description

Public demand for emerging biomedical technologies is higher than ever. Patients, investors and philanthropic supporters find themselves in unfamiliar territory, now as consumers of cutting edge medical options which require diligence and careful consideration. There is little direction and sound resources for the patient consumer to understand the what, where and who(?) regarding investments of time, money and risk in fields like regenerative medicine and stem cell therapies, age management medicine, nutrition and supplementation and genetic testing. The piece will introduce Dr. David Karli, who has had unique and intensive exposure to these emerging medical and scientific fields. Is tomorrow’s medicine here today? Is modern med-tech hope or hype?

Get in contact with David C. Karli through his website, LinkedIn, and learn more about Greyledge Technologies here:

davidkarli.com

https://www.linkedin.com/in/davidkarli/

https://www.greyledgebiotech.com/

(Visited 1 times, 1 visits today)